Mirati gets a standard review for its ‘breakthrough’ KRAS drug. And that is causing some hand wringing

Bioregnum Opinion Column by John Carroll

After the market close on Monday, Mirati issued a statement that the FDA had accepted its delayed application for their KRAS drug adagrasib and is giving it a standard 10-month review, setting a PDUFA date way out toward the…